BioAge Labs (NASDAQ:BIOA) Sets New 52-Week High – Time to Buy?

BioAge Labs, Inc. (NASDAQ:BIOA)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $24.42 and last traded at $24.5980, with a volume of 180857 shares traded. The stock had previously closed at $22.83.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BIOA. BTIG Research initiated coverage on BioAge Labs in a research report on Wednesday, May 13th. They set a “buy” rating and a $40.00 price target on the stock. Roth Mkm initiated coverage on BioAge Labs in a research report on Wednesday, May 27th. They issued a “buy” rating and a $36.00 target price for the company. Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Citigroup lifted their price target on shares of BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Finally, Oppenheimer assumed coverage on shares of BioAge Labs in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.50.

BioAge Labs Trading Up 0.8%

The firm has a fifty day moving average of $17.79 and a two-hundred day moving average of $17.75. The company has a market capitalization of $1.02 billion, a PE ratio of -9.54 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.19. The firm had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. On average, equities analysts expect that BioAge Labs, Inc. will post -2.68 EPS for the current fiscal year.

Hedge Funds Weigh In On BioAge Labs

A number of hedge funds have recently modified their holdings of BIOA. Janus Henderson Group PLC raised its stake in shares of BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after acquiring an additional 1,685,063 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of BioAge Labs in the 4th quarter worth approximately $13,892,000. Stempoint Capital LP bought a new stake in shares of BioAge Labs in the 1st quarter worth approximately $5,923,000. Millennium Management LLC increased its stake in shares of BioAge Labs by 749.8% during the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after buying an additional 270,479 shares during the period. Finally, Sphera Funds Management LTD. bought a new position in shares of BioAge Labs during the fourth quarter valued at approximately $3,215,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.